What's Happening?
IDB Invest has announced a financing package of up to $10 million for Ancalmo S.A. de C.V., a Salvadoran pharmaceutical company, to expand and modernize its production capabilities. The funding will be used to refurbish and expand production facilities,
acquire new machinery, and strengthen working capital. This initiative aims to boost local pharmaceutical production, enhance export capacity, and generate employment in El Salvador and the broader Central American region. The financing includes a committed tranche of $8 million and an uncommitted tranche of up to $2 million, with a term of up to eleven years.
Why It's Important?
This investment is crucial for strengthening El Salvador's pharmaceutical sector, which plays a vital role in the country's economic development and public health. By enhancing production capacity and modernizing facilities, Ancalmo can increase its competitiveness in regional markets, potentially leading to greater economic growth and job creation. The project also aligns with broader efforts to improve healthcare access and quality in the region. IDB Invest's support reflects a commitment to fostering sustainable development and innovation in strategic sectors like pharmaceuticals.
